FDA recently announced the approval of Probuphine, an implantable form of buprenorphine, for treating opioid dependence. National Public Radio sought the views of Dr. Cidambi, addiction expert and medical director of the Center for Network Therapy, on the medication.
Dr. Cidambi is a leader in addiction treatment and innovator of safe and effective ambulatory (outpatient) detoxification level of care for alcohol, benzodiazepines, opiates, and suboxone. Prior to founding the Center for Network Therapy, she completed her residency in Psychiatry at Maimonides Medical Center in Brooklyn and an Addiction Medicine Fellowship at NYU/Bellevue Hospital in New York. Due to the successful detoxification program, Dr. Cidambi was featured frequently by media outlets, including NPR, CBS, NY Times, and Wall Street Journal.